On Wednesday, Baird, a financial services company, increased its stock price target on Sherwin-Williams (NYSE:SHW) shares to $360 from the previous $350 while maintaining a Neutral rating on the stock. The adjustment reflects expectations for the company's growth, particularly with regard to industry volume growth anticipated in 2025.
The analyst at Baird pointed out that despite sluggish end-markets and pressure from elevated interest rates, including a recent uptick, the firm's stance on Sherwin-Williams remains unchanged. The Neutral rating is supported by a conservative view of the current market conditions affecting the company.
Looking ahead, Baird's price target is underpinned by the expectation that Sherwin-Williams will be able to implement an additional 5% price increase in 2025. This increase is seen as a key factor in the company's ability to achieve growth in the coming years.
The $360 price target set by Baird is based on an estimated 26 times the firm's 2026 earnings per share (EPS) projection of $13.75. This valuation reflects a positive outlook on Sherwin-Williams' financial performance over the next two years.
Sherwin-Williams, a global leader in the manufacture, development, distribution, and sale of paints, coatings, and related products, is poised to capitalize on industry growth as projected by Baird's analysis. The company's stock will continue to be observed by investors as it navigates the challenges and opportunities of the market.
In other recent news, Sherwin-Williams has experienced a series of developments. Despite a challenging first half of 2025, the company reported a 2.2% growth in same-store sales for the Paint Stores Group in the third quarter of 2024.
However, the company's two other segments saw a decline in sales due to unfavorable foreign exchange rates and reduced do-it-yourself volumes. Sherwin-Williams also announced a 5% price increase for January, which is expected to contribute to margin expansion.
Analysts from Goldman Sachs (NYSE:GS) and Evercore ISI provided their perspectives on these developments. Goldman Sachs maintained a Buy rating for Sherwin-Williams, citing the company's historical strategy of investing during challenging times to gain market share.
Meanwhile, Evercore ISI reduced its price target from $410 to $400, but retained an Outperform rating on the stock. Both firms acknowledged the company's recent earnings miss but remained optimistic about Sherwin-Williams' future prospects.
Furthermore, Sherwin-Williams reported consolidated sales growth, improved gross margins, and increased earnings per share in the third quarter of 2024, despite temporary store closures due to hurricanes. The company also returned $631 million to shareholders through dividends and share repurchases. These recent developments indicate Sherwin-Williams' resilience in the face of market challenges and its commitment to shareholder value.
InvestingPro Insights
Sherwin-Williams' financial metrics and market performance align with Baird's cautiously optimistic outlook. According to InvestingPro data, the company boasts a substantial market capitalization of $91.16 billion, reflecting its strong position in the chemicals industry. The company's revenue for the last twelve months stands at $23.05 billion, with a modest growth of 0.1%, indicating stability in challenging market conditions.
InvestingPro Tips highlight Sherwin-Williams' commitment to shareholder value. The company has raised its dividend for 32 consecutive years and has maintained dividend payments for 46 years, demonstrating financial resilience. This aligns with Baird's expectation of the company's ability to implement price increases and achieve growth.
However, investors should note that Sherwin-Williams is trading at a high P/E ratio of 38.05, which is consistent with Baird's conservative stance. This valuation metric suggests that the stock may be priced at a premium relative to its earnings.
For readers interested in a deeper analysis, InvestingPro offers 15 additional tips for Sherwin-Williams, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.